Paciente · kg
🤢

Prometazina

Promethazine Hydrochloride

AntieméticosMOL
ADVERTENCIA DE CAJA NEGRA — FDA

PROMETHAZINE HCl SUPPOSITORIES SHOULD NOT BE USED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE BECAUSE OF THE POTENTIAL FOR FATAL RESPIRATORY DEPRESSION. POSTMARKETING CASES OF RESPIRATORY DEPRESSION, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH USE OF PROMETHAZINE HCl SUPPOSITORIES IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. A WIDE RANGE OF WEIGHT-BASED DOSES OF PROMETHAZINE HCl SUPPOSITORIES HAVE RESULTED IN RESPIRATORY DEPRESSION IN THESE PATIENTS. CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE HCl TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER. IT IS RECOMMENDED THAT THE LOWEST EFFECTIVE DOSE OF PROMETHAZINE HCl BE USED IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER AND CONCOMITANT ADMINISTRATION OF OTHER DRUGS WITH RESPIRATORY DEPRESSANT EFFECTS BE AVOIDED.

DESCRIPCIÓN CLÍNICA

Antihistamínico H1 + antiemético. NV, sedación. EXTRAVASACIÓN: necrosis severa. Vía central preferida.

DOSIS CLÍNICAS — 1 indicación

// verifica con ficha técnica
ADULTO
Náusea y vómito / sedación adyuvanteIV · cada 4-6 h según necesidad
6.25–25 mgmáx 100 mg/día

Antihistamínico H1/antagonista D2. ADVERTENCIA FDA caja negra: lesión tisular grave/gangrena con IV; preferir IM, diluir (<=25 mg/mL), dar lento (<=25 mg/min), vía grande. En ancianos 6.25 mg tan efectivo como 12.5 mg. No en <2 años (depresión respiratoria fatal). [FDA / UpToDate]

// dosis aproximadas de literatura aceptada (Stoelting, Miller's, Lexicomp, fichas técnicas FDA/EMA).
// titular según respuesta clínica, comorbilidades y monitorización.
// poblaciones especiales no listadas → consultar ficha técnica.

ESTRUCTURA QUÍMICA

DATOS MOLECULARES
rendering...
Fórmula
C17H20N2S
Peso molecular
284.40 g/mol
LogP
4.80Lipofílico
Alta penetración tisular; SNC accesible
IDENTIFICADORES QUÍMICOS
SMILES
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
InChI Key
PWWVAXIEGOYWEE-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3

EFECTOS ADVERSOS

life
Convulsiones
SNC · common
mode
Bradicardia
Cardiovascular · common
mode
Taquicardia
Cardiovascular · common
mode
Trombocitopenia
Hematológico · common
mild
Confusión
SNC · common
mild
Depresión
SNC · common
mild
Edema
Sistémico · common
mild
Fatiga
Sistémico · common
mild
Insomnio
SNC · common
mild
Leucopenia
Hematológico · common
mild
Mareo
SNC · common
mild
Náuseas
Gastrointestinal · common
mild
Somnolencia
SNC · common
mild
Temblor
SNC · common
mild
Vómitos
Gastrointestinal · common

ADVERTENCIAS Y CONTRAINDICACIONES

WARN

WARNINGS PROMETHAZINE HCl SUPPOSITORIES SHOULD NOT BE USED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE BECAUSE OF THE POTENTIAL FOR FATAL RESPIRATORY DEPRESSION. POSTMARKETING CASES OF RESPIRATORY DEPRESSION, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH USE OF PROMETHAZINE HCl SUPPOSITORIES IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. A WIDE RANGE OF WEIGHT-BASED DOSES OF PROMETHAZINE HCl SUPPOSITORIES HAVE RESULTED IN RESPIRATORY DEPRESSION IN THESE PATIENTS. CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE HCl TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER. IT IS RECOMMENDED THAT THE LOWEST EFFECTIVE DOSE OF PROMETHAZINE HCl BE USED IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER AND CONCOMITANT ADMINISTRATION OF OTHER DRUGS WITH RESPIRATORY DEPRESSANT EFFECTS BE AVOIDED. CNS Depression - Promethazine HCl Suppositories may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating ma

EMBARAZO Y LACTANCIA

B/C. Metoclopramida y ondansetrón aceptables.

OTROS ANTIEMÉTICOS

⚕️ Información de referencia clínica. Verifique dosis, dilución y vía antes de administrar. No sustituye el juicio profesional ni la ficha técnica oficial. Ver descargo.